The American Heart Association (ACC) Annual Scientific Session is the top international academic event in clinical cardiovascular field. 20,000 cardiovascular specialists from around the world participated in ACC 2016 to present the latest academic achievements, exchange the newest academic view and to release the latest clinical research.

On the morning of April 3rd Chicago local time, Professor Ben He of our hospital, on behalf of Chinese specialists, delivered a keynote speech on “pharmacoinvasive strategy is non-inferior to primary PCI for STEMI”. Professor He reported the latest multi-center clinical trial data of pharmacoinvasive strategy in Chinese population to international cardiovascular counterparts. The results indicated that there was no significant difference in myocardial injury according to magnetic resonance between STEMI patients who accepted early PCI following thrombolysis and those underwent primary PCI.

Professor He and his team have been dedicated to the first aid in myocardial infarction for many years. They carried out systematic series of studies in the choice of thrombolysis and PCI, the optimal pathway of early PCI and many other aspects. At current ACC meeting, Professor He was invited to present the comparison results of cardiac injury according to magnetic resonance between early PCI following thrombolysis (i.e. pharmacoinvasive strategy)and primary PCI. The study found that in patients within 6 hours of symptom onset who were randomized to receive thrombolysis plus PCI or primary PCI, there was no significant difference in cardiac function, micro-vascular obstruction (MVO), myocardial hemorrhage (IMH) and other indicators between the two groups. The study demonstrated that in specific subgroups of patients, pharmacoinvasive strategyis non-inferior to primary PCI and was a good choice.

STEMI is the most critical cardiovascular emergency, with acute onset and high mortality. Early recovery of coronary blood flow and rescue of myocardium are crucial to saving patients’ lives. Pharmacoinvasive strategy provides more choices for clinicians and patients, especially in the vast underdeveloped areas of our country. It is an important treatment measures that deserves promotion when there is no condition for primary PCI. The study of Professor He and his team has positive and practical significance on the improvement of China’s STEMI reperfusion treatment and patients’ clinical prognosis.

Professor He's lecture won wide repercussions in both domestic and foreign academic circles. Recently, several international mainstream cardiovascular academic media including ACC website, international circulation and heart online reported this study from Renji Hospital,Shanghai Jiaotong University School of medicine, in the title of "Chinese sound on ACC ". Moreover, the reports gained continuous reprint and highly attention in several Chinese Wechat Group.

Correspondent  Lingcong Kong , Translator Yujun Sun